1
|
Hotton J, Gauchotte G, Mougel R, Migliorini M, Lacomme S, Battaglia-Hsu SF, Agopiantz M. Expressions of HuR, Methyl-HuR and Phospho-HuR in Endometrial Endometrioid Adenocarcinoma Are Associated with Clinical Features. Int J Mol Sci 2024; 25:954. [PMID: 38256026 PMCID: PMC10815350 DOI: 10.3390/ijms25020954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/03/2024] [Accepted: 01/09/2024] [Indexed: 01/24/2024] Open
Abstract
HuR regulates cytoplasmic mRNA stability and translatability, with its expression correlating with adverse outcomes in various cancers. This study aimed to assess the prognostic value and pro-oncogenic properties of HuR and its post-translational isoforms methyl-HuR and phospho-HuR in endometrial adenocarcinoma. Examining 89 endometrioid adenocarcinomas, we analyzed the relationship between HuR nuclear or cytoplasmic immunostaining, tumor-cell proliferation, and patient survival. HuR cytoplasmic expression was significantly increased in grade 3 vs. grade 1 adenocarcinomas (p < 0.001), correlating with worse overall survival (OS) (p = 0.02). Methyl-HuR cytoplasmic expression significantly decreased in grade 3 vs. grade 1 adenocarcinomas (p < 0.001) and correlated with better OS (p = 0.002). Phospho-HuR nuclear expression significantly decreased in grade 3 vs. grade 1 adenocarcinomas (p < 0.001) and non-significantly correlated with increased OS (p = 0.06). Cytoplasmic HuR expression strongly correlated with proliferation markers MCM6 (rho = 0.59 and p < 0.001) and Ki67 (rho = 0.49 and p < 0.001). Conversely, these latter inversely correlated with cytoplasmic methyl-HuR and nuclear phospho-HuR. Cytoplasmic HuR expression is a poor prognosis marker in endometrioid endometrial adenocarcinoma, while cytoplasmic methyl-HuR and nuclear phosphoHuR expressions are markers of better prognosis. This study highlights HuR as a promising potential therapeutic target, especially in treatment-resistant tumors, though further research is needed to understand the mechanisms regulating HuR subcellular localization and post-translational modifications.
Collapse
Affiliation(s)
- Judicaël Hotton
- Department of Gynecology and Obstetrics, CHRU de Nancy, Université de Lorraine, 54000 Nancy, France;
- INSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France; (G.G.); (R.M.); (M.M.); (S.-F.B.-H.)
| | - Guillaume Gauchotte
- INSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France; (G.G.); (R.M.); (M.M.); (S.-F.B.-H.)
- Department of Biopathology CHRU of Nancy, Institut de Cancérologie de Lorraine, BBB, CHRU de Nancy, Université de Lorraine, 54511 Vandœuvre-lès-Nancy, France
- Centre de Ressources Biologiques, BB-0033-00035, CHRU de Nancy, 54000 Nancy, France;
| | - Romane Mougel
- INSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France; (G.G.); (R.M.); (M.M.); (S.-F.B.-H.)
- Department of Reproductive Medicine, CHRU de Nancy, Université de Lorraine, 54000 Nancy, France
| | - Mégane Migliorini
- INSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France; (G.G.); (R.M.); (M.M.); (S.-F.B.-H.)
| | - Stéphanie Lacomme
- Centre de Ressources Biologiques, BB-0033-00035, CHRU de Nancy, 54000 Nancy, France;
| | - Shyue-Fang Battaglia-Hsu
- INSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France; (G.G.); (R.M.); (M.M.); (S.-F.B.-H.)
| | - Mikaël Agopiantz
- INSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France; (G.G.); (R.M.); (M.M.); (S.-F.B.-H.)
- Department of Reproductive Medicine, CHRU de Nancy, Université de Lorraine, 54000 Nancy, France
| |
Collapse
|